Although molecular driver events such as EGFR, TP53, KRAS, and BRCA1 mutations, as well as GI, are already reported to be associated with survival and drug resistance (Feng et al., 2015), clear perception of their relationship with the clinical outcomes remains to be an unmet need in NSCLC. The gene discussed is TP53; the disease is non-small cell lung carcinoma.